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n 2013, >30 000 deaths were directly caused by aortic valve disease (AVD) in the United States, making it the second-leading cause of cardiovascular mortality. 1 Although AVD is an aging-related disease, the prevalence of moderate or severe aortic stenosis in the general population >75 years old is ≈3%. Although ≈50% of patients with severe aortic stenosis are referred for aortic valve replacement, only 40% are actually admitted for aortic valve replacement. Transcatheter aortic valve replacement provides a less-invasive approach than surgical replacement, but it is currently only applied for those patients who were not suitable for traditional aortic valve replacement surgeries. 2 All those put AVD an increasing burden on the healthcare system as global life expectancy increases. 3, 4 Currently, AVD is no longer thought to be a passive process involving fatigue or deterioration of the valve with age but an active, cellular-driven disease that is not an inevitable consequence of aging. 5 Although AVD shares several risk factors and mechanisms with vascular diseases (eg, atherosclerosis), there are fundamental differences between arteries and the aortic valve with respect to disease mechanisms and responses to therapeutic interventions. 6 Fibrotic aortic valve disease (FAVD) is an important pathological fibrotic process that eventually leads to aortic valve stiffening and aortic stenosis, but the pathological mechanism of the initiation and development of FAVD remain elusive. This is a critical barrier for the development of effective pharmacological therapy for preventing or curing FAVD. Klotho (KL) was originally identified as a putative antiaging gene and is predominately expressed in kidneys. 7 Both human and mouse SKL gene are alternatively spliced after exon 3, which encodes the KL1 repeat of Klotho, called secreted klotho (Skl; ≈65 kDa). 8 Skl circulates in the blood as a hormone and regulates function in organs and cells that do not express KL. 9 The protein level of SKL in the blood declines with the age after 40 years. 10 By age 75 years, the serum level of Klotho is about a half of what it was at age 40 years. 10 However, the prevalence of AVD and aortic valve stenosis increases with age.
11 Klotho-deficient mice display multiple phenotypes resembling human aging. 7, 9 A reduction in the level of circulating klotho is also observed in chronic kidney disease, hypertension, and diabetes mellitus. [12] [13] [14] [15] However, whether and how klotho serves as a beneficial and protective factor for FAVD has never been investigated.
The SAMP1/YiFc (SAMP1) murine model was originally derived from brother-sister breeding of AKR/J mice. 16, 17 These mice show accelerated senescence and age-dependent pathologies without any experimental manipulation, 18 including senile amyloidosis, deficits in learning and memory, degenerative joint disease, and decline in immune responsiveness. Here we reported, for the first time, that SAMP1 mice developed severe aortic valve fibrosis that was associated with a decrease in serum klotho levels. The goal of this study was to determine whether klotho has beneficial effect on inflammation-related FAVD in senescence-accelerated mice P1 (SAMP1) mice.
In the present study, we provided evidence that SAMP1 mice carry innate immune defect in the aortic valve. This manifests itself in vivo as an ideal model to study inflammation-induced aortic valve fibrosis. This dysfunctional immune response is specifically present in the aortic valve interstitial cells, including increased monocyte infiltration, macrophage invasion, myofibroblast differentiation, and transforming growth factor (TGF) β1 activation, which eventually leads to collagen deposition on the aortic valve in SAMP1 mice. We also found that serum level of klotho was decreased in SAMP1 mice. Adeno-associated virus (AAV) delivery of mouse secreted Klotho increased serum Klotho levels, inhibited the inflammatory responses, and attenuated fibrosis on the aortic valve in SAMP1 mice.
Research Design and Methods
The data and analytic methods are available from the corresponding author on reasonable request.
Animal Study
This study was performed according to the guidelines of the National Institutes of Health on the Care and Use of Laboratory Animals. This project was approved by the University of Oklahoma Health Sciences Center Institutional Animal Care and Use Committee. All mice were housed in cages at room temperatures (25°C±1°C) and were provided with Purina laboratory chow (no. 5001) and tap water. After euthanasia, all animals were perfused transcardially with heparinized PBS under deep anesthesia with ketamine (90 mg/kg) and xylazine (10 mg/kg, IP).
The accelerated senescence-prone strain SAMP1/YitFcs mice and the aged-matched AKR/J mice (controls), from which SAMP1 mice were derived, were purchased from the Jackson Laboratory. At 10 months of age, the animals received a single injection of AAV-SKL or AAV2-GFP (green fluorescent protein) via tail veins. The viral particles were delivered IV at 1.2×10
8 PFU (plaque-forming unit)/100 μL per mouse. The animals were divided into 3 groups (5 mice/ group): AKR/J mice, SAMP1 mice injected with AAV2-GFP (SAMP1+GFP), and SAMP1 mice injected with AAV2 carrying mouse Skl cDNA (SAMP1+Skl). 
Construction of Recombinant AAV With the Mouse Secreted Klotho (Skl) Gene
The procedure for constructing the recombinant AAV2 carrying the mouse secreted klotho cDNA was described in our previous studies. 12, 19 AAV carrying GFP were constructed as control constructs.
Tissue Collection
At 24 weeks after AAV delivery, animals were euthanized using an overdose of ketamine (180 mg/kg body weight) and xylazine (20 mg/kg body weight), and blood was collected with heparin as an anticoagulant. After blood collection, animals were perfused transcardiacally using heparinized saline. 19, 20 The upper part of the heart along with 3 mm of ascending aorta was placed in 4% paraformaldehyde in PBS for 24 hours and then embedded in paraffin.
Histological Staining
A series of 5-µm cross-sections of the aortic valve were cut and stained using the Masson Trichrome Staining Kit (EMS, Hatfield, PA). Immunohistochemical procedures were performed as described in our previous studies. [13] [14] [15] [21] [22] [23] [24] Briefly, immunohistochemical staining against antibodies of MCP-1 (monocyte chemoattractant protein 1; Cell Signaling, 2029), ICAM-1 (intercellular adhesion molecule 1; Santa Cruz, sc-8439), F4/80 (Biolegend, 123102), CD68 (abcam, ab955), TGFβ-1 (Santa Cruz, sc-146), scleraxis (SCXA; abcam, ab58655), α-SMA (smooth muscle actin; abcam, ab7817), TRAP (Tartrate-resistant acid phosphatase; ProteinTech. 11594-1-AP), and MMP-2 (abcam, ab37150) was performed using the respective ABC staining system (Santa Cruz Biotechnology). Images of aortic valves were collected at the same exposure conditions under a Nikon Eclipse Ti microscope (×10, ×20, and ×40 objective). The fractional areas of collagen fibrosis components (blue, trichrome staining; brown, immunohistochemical staining) in the aortic valve region were obtained using National Institutes of Health image J software.
Western Blot Analysis
Western blot analysis was performed as we described in our recent studies. 13, 14, 25 Briefly, an equal amount of serum from AKR/J and SAMP1 mice was diluted, treated with ×4 Laemmli Sample buffer (Bio-RAD, Hercules, CA) and loaded on a 4% to 20% Express Plus PAGE gel (GenScript, NJ). The protein was transferred onto nitrocellulose filters after separation in the gel. Blots were blocked in 1% BSA in Tris-buffered saline with Tween for 1 hour at room temperature, and the membranes were incubated with klotho primary antibody (R&D systems, AF1819) at 4°C overnight. The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room temperature. Proteins were visualized, examined, and quantified by densitometry using ChemDoc XRS with Quantity One Software (Bio-RAD). Membranes were incubated in Ponceau stain for internal loading control.
Statistical Analysis
Quantitative data were presented as the mean±SE. Data were analyzed using 1-way ANOVA. The Newman-Keuls procedure was used to assess differences between means. Data were expressed as mean±SEM. P<0.05 was considered significant.
Results

Aortic Valve Fibrotic Formation Was Associated With Decreased Serum Klotho Levels in SAMP1 Mice
Masson trichrome staining of the aortic valves of SAMP1 mice showed significantly increased collagen deposition compared with the aortic valves of the age-matched AKR/J mice ( Figure 1A ). The collagen deposition preferentially accumulated on the aortic surface (solid arrows, Figure 1B ) compared with the ventricular surface of the leaflets (dashed arrows). This observation indicated a typical development of FAVD in the SAMP1 mice. Because SAMP1 is a senescence-accelerated model, we measured serum levels of secreted klotho (SKL), an antiaging protein, in SAMP1 and AKR/J mice using immunoblotting. The serum level of SKL in SAMP1 mice is about a half of that of the age-matched AKR/J mice ( Figure 1D and 1E) . Therefore, it would be intriguing to investigate whether the decreased serum level of klotho contributes to the formation of FAVD in SAMP1 mice.
In Vivo AAV2 Delivery of SKL Restored the Serum Klotho Level and Attenuated Fibrosis in the Aortic Valve of SAMP1 Mice
To investigate whether an increase in serum secreted klotho levels rescues SAMP1 mice from FAVD, we overexpressed Skl by in vivo delivery of AAV2 carrying mouse Skl cDNA. Indeed, delivery of Skl restored serum level of klotho of SAMP1 mice to the level of age-matched AKR/J control mice ( Figure S1 in the online-only Data Supplement). On the aortic valves, Masson trichome staining of collagen deposition showed that restoration of serum klotho levels significantly attenuated fibrosis and collagen accumulation on the leaflets and the entire aortic valves in SAMP1 mice (Figure 2 ).
Restoration of Serum Klotho Levels Inhibited MCP-1 and ICAM-1 Expression and Decreased Macrophage Infiltration in SAMP1 Mice
We further investigated how increased serum Skl inhibited fibrosis on the aortic valve. Our previous study demonstrated that klotho deficiency mice fed with high-fat diet developed FAVD through AMPKα (5′ adenosine monophosphate-activated protein kinase alpha)-mediated activation of Runx2 (runt-related transcription factor 2). 26 However, immunohistochemical staining of aortic valves against Runx2, BMP2 (bone morphogenetic protein 2), and BMP4 antibodies did not show any difference between SAMP1, SAMP1+mskl, and AKR/J mouse ( Figure S2 ), suggesting that the Runx2 pathway may not be involved in the development of FAVD in SAMP1 mice.
Although SAMP1 is a well-known accelerated aging model, there has been no report about AVDs in SAMP1 mouse. MCP-1 and ICAM-1 are critical factors that drive monocyte infiltration. Immunohistochemical staining showed that MCP-1 and ICAM-1 levels were increased on the aortic valve of SAMP1 mice, which were decreased significantly by restoration of serum klotho levels ( Figure 3) . Consequently, the macrophage marker F4/80 and CD68 was drastically increased in aortic valves of SAMP1 mice (Figure 4 ). Inflammation would lead to the formation of aortic valve fibrosis in SAMP1 mice. The macrophage infiltration was effectively inhibited by restoration of serum klotho levels ( Figure 4) . The therapeutic effect of mSKL on FAVD may be attributed, in part, to its antiinflammatory action.
Restoration of Serum Klotho Levels Inhibited Upregulation of TGFβ-1 and Scleraxis on the Aortic Valve
TGFβ-1 plays a central role in several fibrotic diseases in different organs 27, 28 and exhibits anti-or proinflammatory roles in immunity. Immunohistochemical staining of TGFβ-1 on the aortic valve showed that TGFβ-1 was expressed at a low level in the AKR/J mice but was drastically upregulated in the SAMP1 mice while restoration of serum klotho by overexpression of mSKL significantly decreased TGFβ-1 expression on the aortic valves ( Figure 5 ).
SCXA is a member of the basic helix-loop-helix superfamily of transcription factors and has been identified as a potent profibrotic factor regulating collagen genes. [29] [30] [31] It was reported that TGFβ-1 regulated scleraxis expression in cardiac myofibroblasts. 32 Indeed, upregulation of TGFβ-1 on the aortic valves of SAMP1 mice was associated with increased SCXA expression ( Figure 5) , suggesting that the TGFβ-1 and scleraxis pathway may be involved in the collagen oversynthesis. Restoration of serum klotho attenuated the upregulation of TGFβ-1 and SCXA, suggesting that serum klotho levels regulate the TGFβ-1-SCXA pathway in collagen synthesis in aortic valves.
Restoration of Serum Klotho Inhibited Differentiation of Aortic Valve Interstitial Cells (AVICs) into Myofibroblasts
Myofibroblast differentiation and activation is a critical pathogenetic event leading to human fibrotic diseases 33, 34 and is induced by TGFβ1. 35 α-SMA, a marker of myofibroblasts, was expressed at a low level on the normal aortic valve but was robustly expressed on the aortic valves of SAMP1 mice ( Figure 6 ). Thus, activation of myofibroblasts may play an important role in aortic valve fibrosis formation in this model. Restoration of serum klotho by in vivo expression of SKL significantly decreased the expression of α-SMA (Figure 6 ), suggesting SKL inhibits myofibroblast activation and collagen fibril remodeling in extracellular matrix (ECM) most likely through downregulation of TGFβ1 expression on the aortic valve.
Restoration of Serum Klotho Attenuated Upregulation of TRAP and MMP-2 Expression on the Aortic Valve
TRAP, an osteoclast marker, and MMP-2, a protein involved in ECM remodeling, are expressed in a moderate level in the AVICs. Both proteins play important roles in maintaining the structure and mechanic properties of aortic valves. On the aortic valve of SAMP1 mice, immunohistochemical staining against TRAP and MMP-2 antibodies showed that the expressions of TRAP and MMP-2 were significantly increased ( Figure S3 ). The upregulations of TRAP and MMP-2 were attenuated by restoration of serum klotho ( Figure S3 ).
Discussion
This study demonstrated for the first time that SAMP1 developed FAVD, which may be a useful model for studying agingrelated aortic valve fibrosis. The novel finding is that FAVD may be largely attributed to a decline in serum level of klotho (Figures 1 and 2) , an aging-suppressor protein secreted by other organs (eg, kidneys). Restoration of serum klotho by in vivo delivery of AAV2.Skl effectively attenuated FAVD in SAMP1 mice. Therefore, Skl may serve as an effective therapeutic target for FAVD. It is known that serum levels of klotho decrease gradually after age 40 years 10 while the prevalence of aortic stenosis increases with age. 11 At age 75 years, serum level of klotho is only about half of what it was at age 40 years. 10 In this study, we found that serum level of klotho was reduced by ≈50% in SAMP1 mice (Figure 1) , which mimics the reduction of klotho protein levels in the aged population. 10 AVD including FAVD is a leading cause of adult heart diseases 36, 37 and is the most common form of acquired valvular disease in the United States. 11, 38, 39 FAVD eventually leads to aortic valve stiffening and aortic stenosis. Unfortunately, there currently is no effective therapy for FAVD because of unknown pathogenesis. Therefore, pharmacological introduction of secreted klotho protein may be worthy of further investigations for the treatment of FAVD. Chemical induction of klotho 40 may be tested to treat FAVD. The SAMP1 mouse is known for its defective immune function and enhanced chronic inflammation in the digestive system. [41] [42] [43] [44] We found a robust inflammatory response in the aortic valves in SAMP1 mice, which is characterized by increased levels of MCP-1 and ICAM-1 and infiltration of monocytes/macrophages (Figures 3 and 4) . MCP-1 and ICAM-1 attract monocytes to the injury sites and promote a transition of monocytes to macrophages. The inflammatory damage is a critical factor that causes aortic valve fibrotic remodeling. Aortic valve inflammation is likely because of a decrease in serum klotho levels in SAMP1 mice because restoration of serum klotho significantly attenuated inflammation (Figures 3 and 4) . Klotho directly interacts with valvular interstitial cells and regulates their functions and homeostasis. 26 Klotho deficiency impairs vascular cells, 45, 46 which elicits immune and inflammatory responses by releasing chemokines or cytokines. This study provides the first evidence that klotho may serve as an anti-inflammatory factor that inhibits inflammation in aortic valves. The anti-inflammatory action of klotho may contribute to its antifibrotic effect in aortic valves in SAMP1 mice. Although klotho deficiency may directly cause valvular injury and inflammation, it may also contribute to valvular inflammation indirectly via mechanisms because of klotho deficiency. For example, klotho deficiency is known to cause hypertension, 9 which may contribute to valvular inflammation indirectly. Indeed, we cannot exclude the possibility that the anti-inflammatory effect of Skl in aortic valves may be partially because of a reduction of blood pressure. A further study is needed to test this interesting hypothesis.
A technical challenge for the study of AVD in mice is the limited amount of aortic valve tissue available for molecular assays. We realize the limitation of the immunohistochemical assays, which provides only semiquantitative analysis. It should be mentioned that in vivo delivery of Skl mainly results in expression of Skl in the kidney, 12 a major source of Skl in the blood. 9 Klotho is not expressed in aortic valves or vessels, but the circulating Skl has direct action on valvular and vascular cells. 9 Thus, serum klotho plays a critical role in the regulation of valvular function. It is interesting that a kidney-derived protein is essential in the maintenance of normal valvular homeostasis.
It should be mentioned that SAMP1 mice developed moderate high blood pressure that was also attenuated by AAV.Skl ( Figure S4 ). Although Skl has direct action on valvular cells, 26 we cannot exclude the possibility that the observed improvement in FAVD may be partially attributed to a reduction of hypertension by AAV.Skl. The limitation of this study is that it cannot determine whether the beneficial effects of AAV.Skl on FAVD is because of the direct actions of Skl on valvular cells or secondary to attenuation of high blood pressure. A further study is warranted to investigate whether there is relationship between hypertension and FAVD.
TGFβ1 and its downstream factor SCXA were upregulated in aortic valves of SAMP1 mice ( Figure 5 ), which may be attributed to increased valvular inflammation. Activation of myofibroblasts in the AVICs (Figure 6 ) which is closely regulated by TGFβ1 35 also suggests that the inflammatory response may be involved in fibrotic formation in the aortic valves of SAMP1 mice. It is anticipated that activation of myofibroblasts in AVICs caused by inflammation may go through similar molecular mechanisms that govern the myocardial wound healing process. 34, 47 Aortic valve is a small but critical piece of apparatus that ensures a unidirectional blood flow in the cardiovascular system. The normal valvular structure and mechanical properties are critical for the maintenance of normal cardiovascular function. Under inflammatory events, activation of myofibroblasts secretes more ECM components, including fibrillar collagen proteins. 47 Increased matrix deposition at this time is required to provide additional structural and tensile strength to the AVICs to prevent aortic valve structural damage. Meanwhile, the matrix-degrading enzymes, such as TRAP and MMP-2, also correspondingly increased on the aortic valve of SAMP1 mouse ( Figure S3) , suggesting that the AVICs may undergo a compensatory process to maintain the homeostasis of the ECM and normal tissue structure in aortic valves. However, other MMP enzymes also stimulate matrix deposition. 48 Thus, increased MMP-2 activity may be an important mechanism contributing to ECM synthesis. Because fibrosis may promote aortic valve calcification, 6 this potent self-protective mechanism of AVICs through cell differentiation and ECM remodeling would eventually lead to aortic valve stiffness, stenosis, and calcification if this process continues to shift to fibrogenesis and osteogenesis direction.
SCXA, a member of the basic helix-loop-helix family of transcription factors, is specifically expressed in tendons and ligaments. SCXA is a critical transcription factor for collagen synthesis. This study showed that SCXA is also expressed in aortic valves ( Figure 5 ). An increase in scleraxis is sufficient to drive expression of the collagen 1α2 gene in primary cardiac fibroblasts. 29, 30 Therefore, upregulation of SCXA ( Figure 5 ) may contribute to the collagen accumulation and ECM remodeling on the aortic valve. Overall, this study sheds light on a new pathway that may mediate the aortic valve fibrotic formation (FAVD; Figure S5 ). 
